PerkinElmer Sells NTD Laboratory Services Business to Eurofins Scientific
April 25 2016 - 7:27AM
Business Wire
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on
improving the health and safety of people and the environment,
today announced that it sold its U. S. prenatal screening
laboratory services business PerkinElmer Labs/NTD (“NTD”) to
Eurofins Scientific.
“Recent changes to U.S. healthcare reform continue to drive the
consolidation of diagnostics testing towards broader service
providers,” said Prahlad Singh, President, Diagnostics,
PerkinElmer. “Eurofins, with its breadth of testing services and
capabilities, is uniquely positioned to meet the expanding service
needs of NTD’s customers. Furthermore, the divestiture of the NTD
business allows PerkinElmer to concentrate its efforts on
developing innovative maternal fetal health technologies and
solutions for the U.S. Outside the U.S., we will continue to
provide kits, technologies and services through a variety of
channels focused on improving health outcomes for babies and
expectant mothers.”
PerkinElmer offers a comprehensive portfolio of diagnostic
solutions including: prenatal, neonatal and infectious disease
screening, along with molecular diagnostics, through its wide range
of instruments, reagents and assay platforms, and software
offerings. PerkinElmer also provides private cord blood and cord
tissue preservation to families through ViaCord LLC.
NTD generated approximately $20 million in revenue in 2015. The
financial impact of the divestiture, excluding any potential gain
on the sale, is not expected to have a material impact on
PerkinElmer’s 2016 earnings per share guidance which was provided
on February 4th of this year.
About PerkinElmer, Inc.PerkinElmer, Inc. is a global
leader focused on improving the health and safety of people and the
environment. The Company reported revenue of approximately $2.3
billion in 2015, has approximately 8,000 employees serving
customers in more than 150 countries, and is a component of the
S&P 500 Index. Additional information is available through
1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future PerformanceThis press release
contains "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements relating to estimates and projections of
future earnings per share, cash flow and revenue growth and other
financial results, developments relating to our customers and
end-markets, and plans concerning business development
opportunities and divestitures. Words such as "believes,"
"intends," "anticipates," "plans," "expects," "projects,"
"forecasts," "will" and similar expressions, and references to
guidance, are intended to identify forward-looking statements. Such
statements are based on management's current assumptions and
expectations and no assurances can be given that our assumptions or
expectations will prove to be correct. A number of important risk
factors could cause actual results to differ materially from the
results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) markets
into which we sell our products declining or not growing as
anticipated; (2) fluctuations in the global economic and political
environments; (3) our failure to introduce new products in a timely
manner; (4) our ability to execute acquisitions and license
technologies, or to successfully integrate acquired businesses and
licensed technologies into our existing business or to make them
profitable, or successfully divest businesses; (5) our failure to
adequately protect our intellectual property; (6) the loss of any
of our licenses or licensed rights; (7) our ability to compete
effectively; (8) fluctuation in our quarterly operating results and
our ability to adjust our operations to address unexpected changes;
(9) significant disruption in third-party package delivery and
import/export services or significant increases in prices for those
services; (10) disruptions in the supply of raw materials and
supplies; (11) the manufacture and sale of products exposing us to
product liability claims; (12) our failure to maintain compliance
with applicable government regulations; (13) regulatory changes;
(14) our failure to comply with healthcare industry regulations;
(15) economic, political and other risks associated with foreign
operations; (16) our ability to retain key personnel; (17)
significant disruption in our information technology systems; (18)
our ability to obtain future financing; (19) restrictions in our
credit agreements; (20) our ability to realize the full value of
our intangible assets; (21) significant fluctuations in our stock
price; (22) reduction or elimination of dividends on our common
stock; and (23) other factors which we describe under the caption
"Risk Factors" in our most recent quarterly report on Form 10-K and
in our other filings with the Securities and Exchange Commission.
We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160425005696/en/
PerkinElmer, Inc.Investor Relations:Tommy J. Thomas,
781-663-5889tommy.thomas@perkinelmer.comorMedia:Brian Willinsky,
781-663-5728brian.willinsky@perkinelmer.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Apr 2023 to Apr 2024